Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with resectable pancreatic duct adenocarcinoma (PDAC), curative surgery followed by adjuvant chemotherapy is currently the standard of care. However, the long-term results are still poor, with median disease-free and overall survival of 14 months and 23 months. The corresponding 5-year overall survival rate is 20%.

Chemotherapy before surgery (neoadjuvant chemotherapy) allows identification of patients with rapidly progressive metastatic disease at time of preoperative restaging (surgery is then avoided in these patients), and may increase the rate of free margin resection (R0) and reduce the risk of local recurrence.

Even though single-agent gemcitabine and 5-FU have been validated in adjuvant and metastatic settings, the objective response was low (at around 10%), whereas combination chemotherapy exceeds a response rate of 30% in advanced disease. In metastatic PDAC, palliative FOLFIRINOX chemotherapy has been demonstrated to be effective (in terms of response rates and progression-free survival) and well tolerated. Interestingly, the response rate is increased by using more than two chemotherapeutic agents in advanced pancreatic cancer, justifying the use of an alternative neoadjuvant FOLFOX-based chemotherapy arm.

PANACHE-01 is an open, non-comparative, randomised, multicentre Phase II study designed to assess the safety and efficacy of two modes of neo-adjuvant chemotherapy (FOLFIRINOX \& FOLFOX) relative to the current reference treatment (surgery and then adjuvant chemotherapy) for resectable PDAC.

Patients with immediately resectable PDAC (definition based on the NCCN's (American National Comprehensive Cancer Network 2014) latest guidelines) will be randomised to either pancreatectomy and adjuvant chemotherapy or 4 cycles of neoadjuvant chemotherapy with either FOLFOX or FOLFIRINOX. The patients in the neoadjuvant chemotherapy arms will receive postoperative chemotherapy for 4 months (8 cycles).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

NCT02143219

Pancreatic Metastatic Cancer Toxicity

COMPLETED PHASE2

FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

NCT01359007

Adenocarcinoma of Pancreas

TERMINATED PHASE2

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

NCT05529940

Resectable Pancreatic Cancer Neoadjuvant Chemotherapy Effects of Chemotherapy

RECRUITING PHASE3

FOLFIRINOX + NIS793 in Pancreatic Cancer

NCT05417386

Pancreas Cancer Metastatic Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma

TERMINATED PHASE1

A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases

NCT01260415

Colorectal Cancer Liver Metastases

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resectable Pancreatic Duct Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FOLFOX neoadjuvant chemotherapy

4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery

Group Type EXPERIMENTAL

FOLFOX neoadjuvant chemotherapy

Intervention Type DRUG

4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient

curative surgery for resectable pancreatic duct adenocarcinoma

Intervention Type PROCEDURE

curative surgery for resectable pancreatic duct adenocarcinoma

adjuvant chemotherapy

Intervention Type DRUG

8 cycles of standard adjuvant chemotherapy are administrated

FOLFIRINOX neoadjuvant chemotherapy

4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery

Group Type EXPERIMENTAL

FOLFIRINOX neoadjuvant chemotherapy

Intervention Type DRUG

4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient

curative surgery for resectable pancreatic duct adenocarcinoma

Intervention Type PROCEDURE

curative surgery for resectable pancreatic duct adenocarcinoma

adjuvant chemotherapy

Intervention Type DRUG

8 cycles of standard adjuvant chemotherapy are administrated

standard adjuvant chemotherapy

Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.

12 cycles of standard adjuvant chemotherapy are administrated following the surgery

Group Type ACTIVE_COMPARATOR

curative surgery for resectable pancreatic duct adenocarcinoma

Intervention Type PROCEDURE

curative surgery for resectable pancreatic duct adenocarcinoma

Standard adjuvant chemotherapy

Intervention Type DRUG

12 cycles of standard adjuvant chemotherapy are administrated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FOLFOX neoadjuvant chemotherapy

4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient

Intervention Type DRUG

FOLFIRINOX neoadjuvant chemotherapy

4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient

Intervention Type DRUG

curative surgery for resectable pancreatic duct adenocarcinoma

Intervention Type PROCEDURE

Standard adjuvant chemotherapy

12 cycles of standard adjuvant chemotherapy are administrated

Intervention Type DRUG

adjuvant chemotherapy

8 cycles of standard adjuvant chemotherapy are administrated

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histology-proven, adenocarcinoma of the pancreas.
* Resectable adenocarcinoma (according to the NCCN classification 2014): absence of distant organ or distal lymph node metastases, absence of evidence of superior mesenteric vein (SMV) and portal vein distortion, tumour thrombus, or venous encasement, the existence of clear fat planes around the celiac axis, hepatic artery and superior mesenteric artery (SMA). Resectability is evaluated on arterial-phase and portal-phase IV contrast-enhanced multislice CT-scan of the pancreas (slice thickness: 2.5 mm), as evaluated in a multidisciplinary staff meeting including at least one radiologist and one expert surgeon.
* No prior chemotherapy.
* Age 18 years or over.
* Ability to understand and willingness to consent to formal requirements for study participation
* Provision of written informed consent prior to any study-specific screening procedures.

Exclusion Criteria

* PDAC defined as "borderline", locally advanced, non-resectable or metastatic.
* Prior cancer therapy for PDAC
* Surgical or anaesthesiological contra-indications: non-controlled congestive heart failure - non-treated angina - recent myocardial infarction (in the previous year) - non-controlled arterial hypertension (SBP \>160 mm or DBP \> 100 mm, despite optimal drug treatment), long QT, major non-controlled infection, severe liver failure.
* Any medical, psychological or social situation that (in the investigator's opinion) could limit (i) the patient's compliance with the protocol or (ii) the ability to obtain or interpret data.
* Pregnant or breastfeeding women and women of child-bearing age not using effective means of contraception.
* History or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ grade 1, according to according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
* Known hypersensitivity reaction to any of the components of study treatments.
* Pregnancy (the absence of which must be confirmed in a ß-hCG test) or breast-feeding.
* Any significant disease which, in the investigator's opinion, would exclude the patient from the study.
* Patients having been included in a clinical trial within the previous 4 weeks or participating in another trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No